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Abstract
Background: Human abdominal aortic aneurysm (AAA) lesions contain high levels of cathepsin S (CatS), but are deficient in
its inhibitor, cystatin C. Whether plasma CatS and cystatin C levels are also altered in AAA patients remains unknown.
Methods and Results: Plasma samples were collected from 476 male AAA patients and 200 age–matched male controls to
determine CatS and cystatin C levels by ELISA. Student’s t test demonstrated higher plasma levels of total, active, and pro–
CatS in AAA patients than in controls (P,0.001). ROC curve analysis confirmed higher plasma total, active, and pro–CatS
levels in AAA patients than in controls (P,0.001). Logistic regression suggested that plasma total (odds ratio [OR]=1.332),
active (OR=1.21), and pro–CatS (OR=1.25) levels were independent AAA risk factors that associated positively with AAA
(P,0.001). Plasma cystatin C levels associated significantly, but negatively, with AAA (OR=0.356, P,0.001). Univariate
correlation demonstrated that plasma total and active CatS levels correlated positively with body–mass index, diastolic
blood pressure, and aortic diameter, but negatively with the lowest ankle–brachial index (ABI). Plasma cystatin C levels also
correlated negatively with the lowest ABI. Multivariate linear regression showed that plasma total, active, and pro–CatS
levels correlated positively with aortic diameter and negatively with the lowest ABI, whereas plasma cystatin C levels
correlated negatively with aortic diameter and the lowest ABI, after adjusting for common AAA risk factors.
Conclusions: Correlation of plasma CatS and cystatin C with aortic diameter and the lowest ABI suggest these serological
parameters as biomarkers for human peripheral arterial diseases and AAA.
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Introduction
The pathogenesis of abdominal aortic aneurysm (AAA) involves
extensive inflammatory cell infiltration, proteolytic enzyme secre-
tion, and arterial wall extracellular matrix (ECM) protein
degradation. Elastins and collagens are among the most abundant
and best–studied ECM proteins that form the base constituent of
the arterial wall. Proteolytic degradation of these ECM proteins
leads to aortic expansion and rupture. In human AAA, decreased
elastin immunoreactivity and the presence of elastin degradation
associate with increased inflammatory–cell infiltration [1]. Serum
elastin peptide levels correlate with AAA growth rate [2] and
predict late rupture [3]. Type I collagen degradation products are
also increased in AAA lesions – particularly those from patients
with growing or ruptured AAAs [4]. Serum amino terminal pro–
peptide of type III collagen levels are significantly higher in AAA
patients than in those without AAA [5], and significantly and
positively associated with AAA growth rate (r=0.55) among
patients with asymptomatic small AAA [6,7]. Blood levels of
elastin peptide, collagen peptide, and initial AAA size together
may predict the risk of future AAA surgical repair [7].
Cathepsin S (CatS), CatK, and CatL are probably the most
potent mammalian elastases; CatK and CatL are also potent
collagenases [8]. We first detected increased levels of CatS, CatK,
and CatL in human AAA lesions [9,10]. Other cathepsins, such as
CatH and CatB protein levels, are also more than 3–fold higher in
the aortic wall in AAA patients than in those from patients with
arterial occlusive diseases [11]. In contrast, their endogenous
inhibitor, cystatin C, was greatly reduced or deficient in human
AAA lesions or in blood [4,10,11]. We also showed recently that
mice lacking either CatK or CatL were resistant to aortic elastase
perfusion–induced experimental AAA [12,13]. Although not
reported, CatS deficiency also protected mice from aortic elastase
perfusion–induced or Ang–II perfusion–induced experimental
AAA (R.W. Thompson, Y. Qin, and G–P. Shi, unpublished
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AAA in apolipoprotein E–null mice, cystatin C deficiency
significantly expedited AAA formation [14]. These observations
suggest that cysteinyl cathepsins play an important role in human
AAA pathogenesis. But whether we can control AAA growth in
humans by targeting these cathepsins pharmacologically, or
whether their blood concentrations serve as biomarkers for AAA
inflammation or lesion progression, remains unknown.
Although computed tomography (CT), angiography, and
ultrasound remain conventional methods for detecting human
AAA, biomarker screenings have become more common and cost-
effective for evaluating the progression of coronary heart disease,
diabetes, and other associated complications. AAA shares many
risk factors with other cardiovascular diseases and metabolic
disorders. Hypertensive men have a high risk of developing AAA
[15]. Hypertensive rats developed aortic elastase perfusion–
induced AAA much faster than normotensive rats [16]. Cigarette
smoking is another common risk factor of AAA and other
cardiovascular diseases; smoking history associates strongly with
AAA growth in humans (P=0.003) [17]. In mouse elastase
perfusion–induced experimental AAA, exposure to cigarette
smoking increased aortic elastin degradation and enhanced AAA
expansion by 30% [18]. Statins are commonly used as lipid–
lowering agents in patients with coronary heart diseases [19].
While simvastatin and atorvastatin reduce aortic wall metallopro-
teinase (MMP) expression and suppress experimental AAA in mice
[20–22], pravastatin increases human AAA lesion protein levels of
MMP–8, MMP–9, and CatB [23]. The current study was
designed to examine whether plasma CatS and cystatin C levels
associate with AAA size or growth rate when hypertension,
smoking, statin use, and several other common human AAA risk
factors were considered, using a randomized cohort from a
regional population AAA screening trial.
Materials and Methods
Study population
In an ongoing randomized population–based screening trial for
AAA, peripheral arterial disease (PAD), and hypertension in more
than 50,000 men 65–74 years of age in the mid–region of
Denmark [24], baseline plasma samples were taken consecutively
at diagnosis of 476 AAA patients and in 200 age–matched controls
without AAA or PAD. AAA was defined as having maximal aortic
diameter greater than 30 mm, and PAD was defined as an ankle–
brachial index (ABI) lower than 0.90. AAA cases among first–
degree relatives, smoking status, coexisting diabetes mellitus,
hypertension, and use of b–blockers, angiotensin–converting
enzyme (ACE) inhibitors, and statins were recorded. Body–mass
index (BMI) and systolic and diastolic blood pressure were also
measured and recorded. Ankle systolic blood pressure also was
measured as previously validated and reported [25], and maximal
anterior–posterior diameter of the infrarenal aorta was measured
in the peak of the systole from the inner edge to inner edge of
aorta. The lowest ABI was calculated as the lowest recorded ankle
blood pressure divided by the brachial systolic blood pressure.
Patients with AAA less than 50 mm were offered annual control
scans by the screening team; patients with AAA measuring 50 mm
or larger were referred for a CT–scan and vascular surgical
evaluation. The respective departments of vascular surgery
organized surveillance for those who did not undergo surgery.
The interobserver variation of aortic diameter measurements was
1.52 mm [26]. Growth rates of small AAA in patients kept under
surveillance were calculated by individual linear regression
analysis, using all observations. Blood samples were centrifuged
at 3000 g for 12 minutes, aliquoted, and stored at –80uC until
analysis was performed. Written informed consent was obtained
from all subjects before participation, and the study was approved
by the Local Ethics Committee of the Viborg Hospital, Denmark,
and performed in accordance with the Helsinki Declaration. Use
of non–coded human samples was also approved by the Partners
Human Research Committee, Boston, Massachusetts, USA.
ELISA
Plasma total CatS, pro–CatS, and cystatin C levels were
determined blindly using ELISA DueSet kits from R&D Systems
(Minneapolis, MN) (catalog numbers DY1183, DY2227, and
DY1196) according to the manufacturer’s instructions. Levels of
plasma active CatS (also called mature CatS) were determined by
subtracting levels of pro–CatS from those of total CatS.
Statistics
Dichotomous variables were expressed as proportions and
compared by the chi–square test, and reported as odds ratios.
Probability plots (not shown) were used to determine whether
continuous variables were normally distributed, and compared
between controls and cases by Student’s t–test. Receiver–operator
characteristic (ROC) curve analyses were performed non–para-
metrically to test the predictive value of the tests, concerning the
prediction of AAA cases. For analyses of the ROC curves, the null
hypothesis was that the test performed similarly to the diagonal
line – i.e., the area under the curve was 0.5. If the lowest 95%
confidence limit for the area under the curve was above 0.5, a
significant predictive test was present. The optimal cut–off points
were determined, and the respective sensitivity and specificity were
calculated. The potential markers were then tested as independent
predictors of AAA by logistic regression analysis, adjusting for
AAA among first–degree relatives; smoking status; coexisting
diabetes mellitus; hypertension; use of b–blockers, ACE inhibitors,
or statins; BMI; systolic blood and diastolic blood pressure; and the
lowest recorded ABI. The associations between the potential
serological biomarkers were then correlated to maximal aortic
diameter, lowest ABI, and AAA growth rate by Pearson’s
correlation analysis. The best potential serological biomarker
was then tested for independent association with maximal aortic
diameter, lowest ABI, and AAA growth rate, respectively, by
multivariate linear regression analyses, adjusting for the afore-
mentioned potential AAA confounders.
Results
Increased plasma CatS levels in AAA patients
Of 50,000 volunteers, 25,000 were randomized for screening for
PAD, AAA, and hypertension – among which, approximately
75% attended the screening [24]. Of the first 476 consecutively
diagnosed cases of AAA, 385 had small AAA (aortic diameters
smaller than 50 mm) and were offered surveillance ranging from
0.52 to 3.1 years, with an average of 1.6960.57 (mean 6 SD)
years. Patients with AAA measuring 50 mm or more were referred
for a CT scan and to the vascular surgical department to be
evaluated for potential repair. Those not given a surgical referral
were further followed by the department. Such growth data were
not included in this study. Demographic factors and potential
confounders, as well as aortic diameters, lowest ABI, growth rates,
and serological findings are shown and compared between cases
and controls in Table 1. The mean ages were 70.062.8 (mean 6
SD) years and 69.662.8 (mean 6 SD) years among those without
and with AAA, respectively. Plasma cystatin C levels needed
logarithmic transformation to become normally distributed.
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(odds ratio [OR]: 3.63 [2.41–5.48, 95% C.I.], P,0.001) and
hypertensives (OR: 1.42, [1.02–1.98, 95% C.I.], P=0.04) among
AAA patients than among controls. There were also more users of
b–blockers, ACE inhibitors, and statins among AAA patients than
among controls. Statin users were significantly more frequent
among AAA patients than among controls (OR: 2.15, [1.53–3.03,
95% C.I.], P,0.001). AAA patients also had significantly higher
values of BMI (P=0.001) and systolic (P,0.001) and diastolic
(P,0.001) blood pressures, but their lowest ABI (OR: 8.53, [4.08–
17.80, 95% C.I.], P,0.001) values were significantly lower
compared with controls (Table 1). As we anticipated, plasma total
CatS (P,0.001), pro–CatS (P,0.001), and active CatS (P,0.001)
levels were significantly higher in patients with AAA than in
controls. We did not see significant differences in plasma cystatin
C levels, however, between the two groups – either in direct
measurement or after logarithmic transformation (Table 1).
High plasma CatS levels predict AAA and are
independent AAA risk factors
ROC curve analysis demonstrated the significant differences in
human plasma total CatS, pro–CatS, and active CatS levels
between AAA patients and controls (AUC [area under the ROC
curve]=0.76, P,0.001, AUC=0.64, P,0.001, and AUC=0.74,
P,0.001, respectively), with optimal sensitivities and specificities
of 0.70 and 0.70 versus 0.60 and 0.60 versus 0.69 and 0.69,
respectively, but not plasma cystatin C level (AUC=0.52,
P=0.534) (Figure 1). Logistic regression analysis showed that
plasma total CatS, pro–CatS, and active CatS levels are
independent risk factors for aneurysmal disease, and associated
significantly and positively with AAA with OR of 1.33 (95% C.I.:
1.24–1.43, P,0.001); 1.25 (95% C.I.: 1.10–1.41, P,0.001); and
1.21 (95% C.I.: 1.14–1.30, P,0.001), respectively (only total CatS
is shown in Table 2). Among other tested variables, age, current
smoking, statin use, diastolic blood pressure, and PAD all
associated positively with the risk of AAA. PAD and smoking
were the most potent risk factors for AAA, with OR 6.277 (95%
C.I.: 2.730–14.431, P,0.001) and 4.264 (95% C.I.: 2.480–7.331,
P,0.001), respectively. In contrast, diabetes status and logarith-
mized cystatin C levels associated significantly but negatively with
AAA, with OR 0.437 (95% C.I.: 0.215–0.891, P=0.023) and
0.356 (95% C.I.: 0.212–0.595, P,0.001) for diabetes and
logarithmized plasma cystatin C levels, respectively (Table 2).
Correlations of plasma CatS and cystatin C
concentrations with AAA diameter and lowest ABI
Univariate correlation analysis of the potential serological
biomarkers (CatS and cystatin C), BMI, blood pressure, maximal
Table 1. Demographic factors and potential confounders as well as aortic diameters, lowest ABI, growth rates, and serological
findings are shown and compared between cases with AAA and controls.
Controls (N=200) AAA (N=476)
Dichotomous variables No Yes No Yes
Odds ratio
(95% C.I., P-value)
Familiar disposition 194 6 444 32 2.26 (0.93–5.50, P=0.066)
Current smoker 166 34 273 203 3.63 (2.41–5.48, P,0.001)
Diabetes mellitus 172 28 426 50 0.72 (0.44–1.19, P=0.197)
Hypertension 114 86 228 248 1.42 (1.02–1.98, P=0.040)
Use of b–blocker 154 46 339 137 1.34 (0.91–1,99, P=0.133)
Use of ACE inhibitors 158 42 348 128 1.38 (0.93–2.06, P=0.108)
Use of statins 130 70 255 221 2.15 (1.53–3.03, P,0.001)
ABI ,0.90 200 0 352 121 8.53 (4.08–17.8, P,0.001)
Continuous variables Mean SD Mean SD
Students t-test,
P-value
BMI (kg/m
2) 26.22 3.29 27.17 3.51 0.001
Systolic BP (mmHg) 148.3 19.53 155,3 21.26 ,0.001
Diastolic BP (mmHg) 81.1 10.57 87.8 11.91 ,0.001
Lowest ABI 1.10 0.12 0.94 0.19 0.012
Max aortic diameter (mm) 18.3 3.29 40.6 11.7 ,0.001
Growth rate (mm/year) 2.37 2.53
Serological parameters Mean SD Mean SD
Students t-test,
P-value
Total CatS (ng/mL) 10.7 3.67 14.7 4.25 ,0.001
Pro-CatS (ng/mL) 3.05 2.19 3.74 2.00 ,0.001
Active CatS (ng/mL) 7.78 3.37 11.0 3.70 ,0.001
Cystatin C (ng/mL) 948 497 976 550 0.543
Ln [Cystatin C] (ng/mL) 6.75 0.44 6.77 0.47 0.724
doi:10.1371/journal.pone.0041813.t001
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demonstrated that both plasma total CatS and active CatS levels
correlated significantly and positively with BMI, diastolic blood
pressure, and aortic diameter, and negatively with lowest ABI.
Pro–CatS levels correlated significantly and positively only with
aortic diameter. None of these plasma CatS values associated with
AAA growth rate or systolic blood pressure (Table 3). In contrast,
plasma cystatin C levels correlated significantly and negatively
Figure 1. ROC curve analysis for plasma total CatS, pro–CatS, active CatS, and cystatin C levels in predicting AAA. AUC (area under the
ROC curve), and optimal sensitivities and specificities of each serological parameter are shown in the associated table.
doi:10.1371/journal.pone.0041813.g001
Table 2. Logistic regression analysis of total plasma cathepsin S as independent biomarker of aneurysmal disease.
Variables B S.E. P-Value Exp(B) 95,0% C.I. for EXP(B)
Lower Upper
Total CatS (ng/mL) 0.287 0.036 ,0.001 1.332 1.242 1.429
Age (year) 0.082 0.041 0.046 1.085 1.002 1.176
Familiar AAA (No=0, Yes=1) 0.784 0.570 0.169 2.190 0.716 6.691
Current smoking (No=0, Yes=1) 1.450 0.276 ,0.001 4.264 2.480 7.331
Diabetes mellitus (No=0, Yes=1) 20.827 0.363 0.023 0.437 0.215 0.891
Hypertension (No=0, Yes=1) 0.342 0.254 0.178 1.408 0.855 2.317
ACE-inhibitor (No=0, Yes=1) 0.234 0.292 0.423 1.263 0.713 2.238
Beta-blocker (No=0, Yes=1) 0.032 0.277 0.907 1.033 0.601 1.776
Use of statins (No=0, Yes=1) 0.842 0.251 0.001 2.322 1.420 3.798
Systolic BP (mmHg) 20.005 0.008 0.486 0.995 0.980 1.010
Diastolic BP (mmHg) 0.069 0.014 ,0.001 1.071 1.041 1.101
PAD (No=0, Yes=1) 1.837 0.425 ,0.001 6.277 2.730 14.431
Body mass index (kg/m
2) 0.059 0.036 0.099 1.061 0.989 1.138
Ln [Cystatin C] (ng/mL) 21.034 0.263 ,0.001 0.356 0.212 0.595
Constant 29.293 3.544 0.009 ,0.001
doi:10.1371/journal.pone.0041813.t002
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Scatter plots showed significant positive associations of plasma
total CatS (r=0.291, P,0.001), active CatS (r=0.268, P,0.001),
and pro–CatS levels (r=0.105, P=0.006) with maximal aortic
diameters and negative associations of total CatS (r=20.225,
P,0.001) and active CatS (r=20.219, P,0.001) levels with
lowest ABI values (Figure 2A–2C). In contrast, plasma cystatin C
levels correlated significantly and negatively with lowest ABI
(r=20.141, P,0.001), but not with maximal aortic diameters
(r=20.035, P=0.367) (Figure 2D). After depleting 200 age-
matched controls from this population, which may reduce the
power of association analysis and increase the risk of a type 2
Figure 2. Scatter plots of Pearson correlation analysis of plasma total CatS (A), pro–CatS (B), active CatS (C), and cystatin C (D) levels
with maximal aortic diameters and lowest ABI. Both correlation coefficient and P values are indicated for each analysis.
doi:10.1371/journal.pone.0041813.g002
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associated with lowest ABI (r=20.160, P,0.001). All other
associations lost their statistical significance (data not shown).
We used multivariate linear regression analysis to determine
whether plasma CatS or cystatin C levels associated with AAA
size, lowest ABI, or aneurysmal growth rate when these vascular
parameters were considered as individual dependent variables.
When aortic diameter alone was considered as a dependent
variable, we found that levels of plasma total CatS (P,0.001), pro–
CatS (P=0.001), and active CatS (P,0.001) correlated signifi-
cantly and positively with aortic diameter after adjusting for all
other variables, including familial AAA; current smoking; diabetes
mellitus; hypertension; use of ACE inhibitors, b–blockers, or
statins; systolic and diastolic blood pressures; PAD; BMI; and
plasma cystatin C levels (only total CatS is shown in Table 4). In
contrast to univariate correlation analysis, which showed no
significant association between plasma cystatin C and aortic
diameters (P=0.367, Table 3), a multivariate linear regression test
showed that plasma cystatin C levels correlated significantly and
negatively with aortic diameter after the same adjustment of all
remaining variables (P=0.002, Table 4). Plasma cystatin C levels
therefore may be confounded heavily by many common AAA risk
factors.
Among the list, smoking, statin use, diastolic blood pressure, and
BMI associated positively and significantly with aortic diameter,
whereas coexisting diabetes mellitus associated negatively with
aortic diameter, as did cystatin C (Table 4). When lowest ABI was
used as a dependent variable, plasma total CatS (P=0.002), active
CatS (P=0.001), and cystatin C (P=0.046) associated significantly
and negatively with lowest ABI after adjustments for familial AAA;
smoking; coexisting diabetes mellitus; hypertension; use of ACE
inhibitors, b–blockers, or statins; systolic and diastolic blood
pressures; BMI; and aortic diameter. We did not observe a
significant association concerning pro–CatS.
Among all other tested variables, smoking (P,0.001), hyper-
tension (P=0.031), statin use (P=0.016), systolic blood pressure
(P,0.001), and aortic diameter (P,0.001) associated significantly
and negatively with lowest ABI, while diastolic blood pressure and
BMI associated significantly and positively with lowest ABI after
adjustment for all other variables in Table 4. When aneurysmal
growth rate was considered as a dependent variable, however, only
current smoking associated significantly and positively with
aneurysmal growth rate (P=0.003). None of the other variables
reached statistical significance (Table 4). Smoking appears to be a
significant confounding factor of AAA. To assess whether higher
plasma CatS levels in AAA patients (P,0.001, Table 1) were due
to there being more smokers among AAA patients (P,0.001,
Table 1) than among controls, we excluded all smokers from AAA
and control populations. Among remaining non-smokers, 274
AAA patients still had significantly higher plasma total CatS levels
than those in 167 remaining controls (14.5664.20 ng/mL vs.1 0
5663.69 ng/mL, mean 6 SD, P,0.001).
Discussion
CatS was one of the first cysteinyl cathepsins discovered in
human AAA lesions [10]. Its activities in degrading elastin [27],
fibronectin [28], collagen [29], and laminin [29] suggest strongly
its involvement in AAA formation and progression. While the
expression of MMPs and their tissue inhibitors, TIMP–1 and
TIMP–2, increase synchronously in human AAA lesions [30,31],
expression of CatS and its endogenous inhibitor cystatin C is
regulated oppositely in human AAA lesions. Several studies
demonstrated increased CatS expression but greatly decreased
cystatin C expression, or its deficiency, in human AAA lesions
[4,10,11]. The current study analyzed two forms of CatS in
human plasma samples and demonstrated significantly elevated
levels of pro–CatS and its activated form (Table 1). While pro–
CatS seems a weaker biomarker of human AAA, with optimal
sensitivity and specificity at 0.60 and 0.60, active CatS and total
CatS are much stronger AAA biomarkers with optimal sensitivities
and specificities at 0.1 higher than those of pro–CatS (Figure 1).
Although no other plasma cysteinyl cathepsins in AAA patients
have been reported, increased CatS levels may associate with
increased AAA lesion CatS expression [4,10,11] and may serve as
an independent risk factor and biomarker for human AAA.
Indeed, the OR for total CatS, active CatS, and pro–CatS in a
logistic regression model (Table 2) correlated significantly with
AAA, thereby serving as independent AAA risk factors. Deter-
mining the detailed molecular mechanisms by which CatS
participates in AAA formation and progression, however, will
require more robust analysis in experimental AAA and human
AAA lesions.
This study showed that plasma CatS levels (total CatS, pro–
CatS, and active CatS) correlated positively with aortic diameters,
but negatively with lowest ABI, after adjustment of all potential
Table 3. Univariate correlation analysis of potential serological biomarkers, BMI, blood pressure, maximal aortic diameter, lowest
ABI and aneurysmal growth rate.
Serological parameters Statistical method BMI Systolic BP Diastolic BP Aorta diameter Lowest ABI Growth rate
Ln [Cystatin C] (ng/mL) Pearson correlation
coefficient (r)
20.018 20.055 20.011 20.035 20.141 20.021
P-value 0.635 0.161 0.773 0.367 ,0.001 0.707
Total CatS (ng/mL) Pearson correlation
coefficient (r)
0.101 0.030 0.100 0.291 20.225 20.026
P-value 0.009 0.438 0.010 ,0.001 ,0.001 0.633
Pro-CatS
(ng/mL)
Pearson correlation
coefficient (r)
0.054 20.046 20.036 0.105 20.063 20.020
P-value 0.166 0.233 0.361 0.006 0.104 0.971
Active CatS (ng/mL) Pearson correlation
coefficient (r)
0.084 0.047 0.115 0.268 20.219 20.032
P-value 0.030 0.228 0.003 ,0.001 ,0.001 0.541
doi:10.1371/journal.pone.0041813.t003
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Dependent variable:
Aortic diameter Unstandardized coefficients
Standardized
coefficients (Beta) P-Value
B Std. Error
(Constant) 10.115 9.294 0.277
Total CatS (ng/mL) 0.782 0.117 0.256 ,0.001
Familiar AAA (No=0, Yes=1) 1.831 2.223 0.030 0.410
Current smoking (No=0, Yes=1) 3.593 1.090 0.124 0.001
Diabetes mellitus (No=0, Yes=1) 23.616 1.636 20.084 0.027
Hypertension (No=0, Yes=1) 0.437 1.132 0.016 0.700
Use of ACE inhibitor (No=0, Yes=1) 2.271 1.256 0.071 0.071
Use of b-blocker (No=0, Yes=1) 0.903 1.213 0.029 0.457
Use of statins (No=0, Yes=1) 3.607 1.106 0.130 0.001
Systolic blood pressure (mmHg) 20.061 0.032 20.092 0.059
Diastolic blood pressure (mmHg) 0.344 0.057 0.297 ,0.001
Peripheral arterial disease (No=0, Yes=1) 1.640 1.314 0.047 0.212
Body mass index (kg/m
2) 0.440 0.152 0.111 0.004
Ln [Cystatin C] (ng/mL) 23.412 1.123 20.115 0.002
Dependent variable:
Lowest ABI Unstandardized coefficients Standardized coefficients (Beta) P-Value
B Std. Error
(Constant) 1.350 0.127 ,0.001
Total CatS (ng/mL) 20.005 0.002 20.124 0.002
Familiar AAA (No=0, Yes=1) 20.021 0.030 20.026 0.485
Current smoking (No=0, Yes=1) 20.092 0.015 20.237 ,0.001
Diabetes mellitus (No=0, Yes=1) 0.009 0.022 0.016 0.683
Hypertension (No=0, Yes=1) 20.033 0.015 20.090 0.031
Use of ACE inhibitor (No=0, Yes=1) 20.010 0.017 20.024 0.548
Use of b-blocker (No=0, Yes=1) 20.024 0.017 20.057 0.144
Use of statins (No=0, Yes=1) 20.036 0.015 20.098 0.016
Systolic blood pressure (mmHg) 20.002 0.000 20.173 ,0.001
Diastolic blood pressure (mmHg) 0.002 0.001 0.113 0.029
Body mass index (kg/m
2) 0.005 0.002 0.097 0.013
Aortic diameter (mm) 20.002 0.001 20.170 ,0.001
Ln [Cystatin C] (ng/mL) 20.029 0.015 20.073 0.046
Dependent variable:
Aneurysmal growth rate Unstandardized coefficients Standardized coefficients (Beta) P-Value
B Std. Error
(Constant) 3.316 2.674 0.216
Total CatS (ng/mL) 0.007 0.032 0.013 0.829
Familiar AAA (No=0, Yes=1) 0.241 0.564 0.025 0.669
Current smoking (No=0, Yes=1) 0.887 0.292 0.183 0.003
Diabetes mellitus (No=0, Yes=1) 20.563 0.516 20.065 0.276
Hypertension (No=0, Yes=1) 0.175 0.313 0.036 0.577
Use of ACE inhibitor (No=0, Yes=1) 20.293 0.359 20.052 0.415
Use of b-blocker (No=0, Yes=1) 20.326 0.335 20.060 0.332
Use of statins (No=0, Yes=1) 0.216 0.303 0.045 0.476
Systolic blood pressure (mmHg) 20.006 0.009 20.055 0.476
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with our original hypothesis that more advanced AAA may
contain higher levels of CatS in AAA lesions, as well as in the
circulation. CatS uses its activities in degrading ECM [27–29] and
in processing and presenting antigens [32] to promote arterial wall
elastinolysis and leukocyte recruitment [33] and angiogenesis [27],
and to activate lymphocytes [32] – all which are important in AAA
pathogenesis. We have previously shown that patients with
atherosclerotic stenosis had significantly higher serum levels of
CatS than did patients without cardiovascular complications,
before (P,0.04) and after adjustments for cystatin C levels, renal
functions, smoking, and serum glucose levels (P=0.008) [34].
Consistent with our prior findings, plasma CatS levels (total CatS,
pro–CatS, and active CatS) correlated negatively with the lowest
ABI in the multivariate linear regression model (b=20.124,
P=0.002) (Table 4). Surprisingly, plasma CatS levels showed no
correlation with AAA annual expansion rate in either the
univariate correlation analysis (Table 3) or the multivariate linear
regression model (Table 4). Although we currently do not have any
explanation for this finding at the molecular level, it may result
from this study’s relatively short observation time of small AAA
(1.6960.57 years, mean 6 SD) under surveillance, which could
easily have caused failure to demonstrate associations with
aneurysmal growth rate. Extended monitoring in the future may
increase the power of association analysis between plasma CatS
and AAA annual growth rate. But plasma CatS may not associate
with AAA growth rate, regardless of the length of surveillance.
CatS is a lysosomal protease that degrades ECM in situ in the
arterial wall. Enlarged AAA lesions may contain increased cell
infiltration and proliferation. High AAA growth rate reflects fast
lesion cell accumulation and proliferation, which may not affect
overall CatS expression. All of these possibilities or study
limitations warrant further investigation in this or similar patient
populations.
The current study also reflects reduced cystatin C in human
AAA lesions [4,10,11]. Although we did not see significant
differences in plasma cystatin C levels between AAA patients and
control patients (Table 1), and plasma cystatin C did not predict
AAA (Figure 1), logistic regression analysis did demonstrate a
significant correlation of plasma cystatin C with AAA, and cystatin
C served as an independent AAA risk factor (OR =0.356,
P,0.001) (Table 2). While univariate correlation showed that
cystatin C correlated with lowest ABI (P,0.001), but not with
AAA size (P=0.367) (Table 3), multivariate linear regression
analysis demonstrated a significant and negative correlation with
AAA size (b=20.115, P=0.002). In a relatively smaller
randomized mass screening trial (n=142), Lindholt et al. also
found negative correlations between plasma cystatin C levels and
human AAA size (r=20.22) and AAA annual expansion rate
(r=20.24), but no prediction of cases requiring later surgical
repair – i.e., AAA larger than 50 mm [35]. Although the current
study also showed that cystatin C did not discriminate AAA from
ROC curve analysis (sensitivity and specificity are both 0.52), we
did not see an association between cystatin C and AAA annual
growth rate (P=0.399), likely because of the relatively short AAA
observation time discussed above. Nevertheless, this study has
strength in its population–based, relatively large sample sizes that
make selection bias unlikely and information bias concerning
aortic size and ABI minimal, as it used standardized and validated
methods for data analysis.
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